Psi 7977 trials

When the drug enters into the liver cell, both PSI and PSI molecules rapidly get converted into the same active triphosphate. The drug, in a superior form of tablet, has been evaluated in a Phase I clinical study on healthy volunteers.

The dosage of the drug used in the trials varied from 25mg to mg. Preliminary results of the study have shown that there were no adverse events or discontinuations relating to the usage of the drug. Also, no clinically significant changes were reported in vital signs or ECGs.

The primary objective of the study was to assess the safety and pharmacokinetics of the drug in treating HCV-infected patients. Three dose cohorts of the drug were evaluated during the study. This might be especially true for people with easier-to-treat HCV genotypes 2 or 3. Princeton, N. The rapid and consistent antiviral effects and high barrier to resistance demonstrated with PSI to date provide the rationale for additional exploratory regimens in this setting. About Pharmasset Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections.

Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus HCV infection. Pharmasset's primary focus is development of oral therapeutics for the treatment of hepatitis C virus HCV infection. We currently have three clinical-stage product candidates advancing in trials in various populations. Our pyrimidine, PSI, an unpartnered uracil nucleotide analog, is currently under study in three Phase 2b trials in patients with HCV genotypes 1 through 6, including abbreviated duration interferon and interferon-free regimens.

Our purine, PSI, an unpartnered guanosine nucleotide analog, recently reported safety and efficacy data from days of monotherapy as well as 14 days in combination with the pyrimidine, PSI An SVR-endpoint study of the purine-pyrimidine combination is anticipated to begin third quarter Mericitabine RG continues in two Phase 2b trials and one interferon-free trial conducted through a strategic collaboration with Roche.

For more information, see www. An SVR-endpoint study of the purine-pyrimidine combination is anticipated to begin in the third quarter of Mericitabine RG continues in two Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.

Source Pharmasset, Inc. Press release. June 8, Previous Conferences